To contact our customer service, please send an email to [email protected]
A composite outcome of (1) an HbA1c 6.5% together with (2) 10% WL and (3) without episodes of severe or clinically significant hypoglycemia was achieved by 22% of participants at the semaglutide 1 mg group, compared to 32% to 60% at the tirzepatide 5 to 15 mg groups after 40 weeks of treatment, demonstrating the potential of tirzepatide to improve further the current management of people with T2DM and obesity compared to the currently used GLP-1 RAs
A new Australian meta-analysis of more than 85,000 patients, including those with and without diabetes, found GLP-1 receptor agonists reduced the risk of kidney failure by 16%, and the worsening of kidney function by 22%
Japan Studies conducted have shown that the Growth Hormone Interacts with TB500 BPC157 blend in the Healing Process BPC-157 improves fibroblasts lifespan and, consequently, their potential to stimulate soft tissue regeneration with can assist injury recovery (4)
similar clinically to superficial spreading melanoma